The Readout Loud

306 Episodes

1. 283: A CRISPR milestone, algorithms amok, & biotech mixology

   Published: 11/16/2023
2. From Tradeoffs: Can the U.S. put an end to surprise ambulance bills?

   Published: 11/13/2023
3. 282: Lilly’s obesity drug, the power of radiation, & a biotech implosion

   Published: 11/9/2023
4. 281: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO

   Published: 11/2/2023
5. 280: ESMO highlights, Roivant's big deal, & biotech VC on the rise

   Published: 10/26/2023
6. 279: Live from the 2023 STAT Summit

   Published: 10/19/2023
7. 278: Merger Mondays, Ozempic panic, & CRISPR'd pigs

   Published: 10/12/2023
8. 277: Is the Nobel committee evolving? Plus, preventing public health's wiliest virus

   Published: 10/5/2023
9. 276: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech's slump

   Published: 9/28/2023
10. 275: A thorny ALS debate at the FDA, and the promise of artificial wombs

    Published: 9/21/2023
11. 274: Covid’s latest surge, Alnylam at the FDA, & the end of an era

    Published: 9/14/2023
12. 273: Back to school for biotech, Biogen's potential pivot, & Illumina's next chapter

    Published: 9/7/2023
13. 272: Vivek's star turn, leaky drug data, & biotech as family business

    Published: 8/24/2023
14. 271: Racing for gene therapy, a pioneering approval, & startups in the lurch

    Published: 8/18/2023
15. 270: Your guide to Wegovy’s blockbuster heart study

    Published: 8/10/2023
16. 269: Biotech layoffs, eye drug drama, & gene therapy milestones

    Published: 8/3/2023
17. 268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading

    Published: 7/27/2023
18. 267: BridgeBio's big week, Lilly's Alzheimer's data, & succession at Stanford

    Published: 7/20/2023
19. 266: Wegovy in the brain, pivotal Alzheimer's data, & pulling Threads

    Published: 7/13/2023
20. 265: Novavax's CEO promises a turnaround & how Lilly roiled the obesity market

    Published: 6/29/2023